VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Has a HCC diagnosis confirmed by radiology,        │ Has a HCC diagnosis confirmed by radiology,        │     100 │
│ histology, or cytology (fibrolamellar, and mixed   │ histology, or cytology (fibrolamellar, and mixed   │         │
│ hepatocellular/cholangiocarcinoma subtypes are not │ hepatocellular/cholangiocarcinoma subtypes are not │         │
│ eligible)                                          │ eligible)                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has Barcelona Clinic Liver Cancer (BCLC) Stage C   │ Has Barcelona Clinic Liver Cancer (BCLC) Stage C   │     100 │
│ disease or BCLC Stage B disease not amenable to    │ disease or BCLC Stage B disease not amenable to    │         │
│ locoregional therapy or refractory to locoregional │ locoregional therapy or refractory to locoregional │         │
│ therapy and not amenable to a curative treatment   │ therapy and not amenable to a curative treatment   │         │
│ approach                                           │ approach                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has a Child-Pugh A liver score within 7 days prior │ Has a Child-Pugh A liver score within 7 days prior │     100 │
│ to first dose of study medication                  │ to first dose of study medication                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has at least one measurable lesion based on RECIST │ Has at least one measurable lesion based on RECIST │     100 │
│ version 1.1 as determined by investigator          │ version 1.1 as determined by investigator          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has Eastern Cooperative Oncology Group (ECOG)      │ Has Eastern Cooperative Oncology Group (ECOG)      │     100 │
│ performance status of 0 or 1 performed within 7    │ performance status of 0 or 1 performed within 7    │         │
│ days prior to receiving the first dose of study    │ days prior to receiving the first dose of study    │         │
│ medication                                         │ medication                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has documented objective radiographic progression  │ Has documented objective radiographic progression  │     100 │
│ during or after treatment with sorafenib or        │ during or after treatment with sorafenib or        │         │
│ oxaliplatin-based chemotherapy, or else            │ oxaliplatin-based chemotherapy, or else            │         │
│ intolerance to sorafenib or oxaliplatin-based      │ intolerance to sorafenib or oxaliplatin-based      │         │
│ chemotherapy                                       │ chemotherapy                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female participants of childbearing potential must │ Female participants of childbearing potential must │     100 │
│ have a negative urine or serum pregnancy test      │ have a negative urine or serum pregnancy test      │         │
│ within 72 hours prior to receiving the first dose  │ within 72 hours prior to receiving the first dose  │         │
│ of study therapy                                   │ of study therapy                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female and male participants of reproductive       │ Female and male participants of reproductive       │     100 │
│ potential must agree to use adequate contraception │ potential must agree to use adequate contraception │         │
│ starting from the first dose of study medication,  │ starting from the first dose of study medication,  │         │
│ throughout the study period, and for up to 120     │ throughout the study period, and for up to 120     │         │
│ days after the last dose of study medication       │ days after the last dose of study medication       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Is currently participating or has participated in  │ Is currently participating or has participated in  │     100 │
│ a study with an investigational agent or using an  │ a study with an investigational agent or using an  │         │
│ investigational device within 4 weeks of the first │ investigational device within 4 weeks of the first │         │
│ dose of study medication                           │ dose of study medication                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has received sorafenib or oxaliplatin-based        │ Has received sorafenib or oxaliplatin-based        │     100 │
│ chemotherapy within 14 days of first dose of study │ chemotherapy within 14 days of first dose of study │         │
│ medication                                         │ medication                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has had esophageal or gastric variceal bleeding    │ Has had esophageal or gastric variceal bleeding    │     100 │
│ within the last 6 months                           │ within the last 6 months                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has clinically apparent ascites on physical        │ Has clinically apparent ascites on physical        │     100 │
│ examination                                        │ examination                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has portal vein invasion at the main portal branch │ Has portal vein invasion at the main portal branch │     100 │
│ (Vp4), inferior vena cava, or cardiac involvement  │ (Vp4), inferior vena cava, or cardiac involvement  │         │
│ of HCC based on imaging                            │ of HCC based on imaging                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has had clinically diagnosed hepatic               │ Has had clinically diagnosed hepatic               │     100 │
│ encephalopathy in the last 6 months                │ encephalopathy in the last 6 months                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has had a solid organ or hematologic transplant    │ Has had a solid organ or hematologic transplant    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has had prior systemic therapy for HCC in the      │ Has had prior systemic therapy for HCC in the      │     100 │
│ advanced (incurable) setting other than sorafenib  │ advanced (incurable) setting other than sorafenib  │         │
│ or oxaliplatin-based chemotherapy, prior to start  │ or oxaliplatin-based chemotherapy, prior to start  │         │
│ of study medication                                │ of study medication                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has an active autoimmune disease that has required │ Has an active autoimmune disease that has required │     100 │
│ systemic treatment in the past 2 years.            │ systemic treatment in the past 2 years.            │         │
│ Replacement therapy is not considered a form of    │ Replacement therapy is not considered a form of    │         │
│ systemic treatment                                 │ systemic treatment                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has a diagnosis of immunodeficiency or is          │ Has a diagnosis of immunodeficiency or is          │     100 │
│ receiving systemic steroid therapy or any other    │ receiving systemic steroid therapy or any other    │         │
│ form of immunosuppressive therapy within 7 days    │ form of immunosuppressive therapy within 7 days    │         │
│ prior to the first dose of study medication        │ prior to the first dose of study medication        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has had major surgery to liver or other site       │ Has had major surgery to liver or other site       │     100 │
│ within 4 weeks prior to the first dose of study    │ within 4 weeks prior to the first dose of study    │         │
│ medication                                         │ medication                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has had a minor surgery ≤7 days prior to the first │ Has had a minor surgery ≤7 days prior to the first │     100 │
│ dose of study medication                           │ dose of study medication                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has not recovered adequately (i.e., Grade ≤1 or    │ Has not recovered adequately (i.e., Grade ≤1 or    │     100 │
│ baseline) from the toxicity and/or complications   │ baseline) from the toxicity and/or complications   │         │
│ from any intervention prior to study start         │ from any intervention prior to study start         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has a diagnosed additional malignancy within 3     │ Has a diagnosed additional malignancy within 3     │     100 │
│ years prior to first dose of study medication with │ years prior to first dose of study medication with │         │
│ the exception of curatively treated basal cell     │ the exception of curatively treated basal cell     │         │
│ carcinoma of the skin, squamous cell carcinoma of  │ carcinoma of the skin, squamous cell carcinoma of  │         │
│ the skin and/or curatively resected in situ        │ the skin and/or curatively resected in situ        │         │
│ cancers                                            │ cancers                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has a known history of, or any evidence of,        │ Has a known history of, or any evidence of,        │     100 │
│ central nervous system (CNS) metastases and/or     │ central nervous system (CNS) metastases and/or     │         │
│ carcinomatous meningitis                           │ carcinomatous meningitis                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has a history of (non-infectious) pneumonitis that │ Has a history of (non-infectious) pneumonitis that │     100 │
│ required steroids or current pneumonitis           │ required steroids or current pneumonitis           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has an active infection requiring systemic therapy │ Has an active infection requiring systemic therapy │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Is pregnant or breast feeding or expecting to      │ Is pregnant or breast feeding or expecting to      │     100 │
│ conceive or father starting from the first dose of │ conceive or father starting from the first dose of │         │
│ study medication, throughout the study period, and │ study medication, throughout the study period, and │         │
│ for up to 120 days after the last dose of study    │ for up to 120 days after the last dose of study    │         │
│ medication                                         │ medication                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has received prior immunotherapy with an anti-     │ Has received prior immunotherapy with an anti-     │     100 │
│ Programmed Cell Death Receptor 1 (PD-1),           │ Programmed Cell Death Receptor 1 (PD-1),           │         │
│ Programmed Cell Death Receptor Ligand 1 (anti-     │ Programmed Cell Death Receptor Ligand 1 (anti-     │         │
│ PD-L1), or anti-Programmed Cell Death Receptor     │ PD-L1), or anti- Programmed Cell Death Receptor    │         │
│ Ligand 2 (PD-L2) or has previously participated in │ Ligand 2 (PD-L2) or has previously participated in │         │
│ clinical studies with pembrolizumab                │ clinical studies with pembrolizumab                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has a known history of human immunodeficiency      │ Has a known history of human immunodeficiency      │     100 │
│ virus (HIV)                                        │ virus (HIV)                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has untreated active Hepatitis B                   │ Has untreated active Hepatitis B                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has received a live vaccine within 30 days prior   │ Has received a live vaccine within 30 days prior   │     100 │
│ to the first dose of study therapy                 │ to the first dose of study therapy                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has received locoregional therapy to liver         │ Has received locoregional therapy to liver         │      96 │
│ (transcatheter chemoembolization \[TACE\],         │ (transcatheter chemoembolization [TACE],           │         │
│ transcatheter embolization \[TAE\], hepatic        │ transcatheter embolization [TAE], hepatic arterial │         │
│ arterial infusion \[HAI\], radiation,              │ infusion [HAI], radiation, radioembolization, or   │         │
│ radioembolization, or ablation) within 4 weeks     │ ablation) or other site within 4 weeks prior to    │         │
│ prior to the first dose of study medication        │ the first dose of study medication                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has a life expectancy of \>3 months                │ Has a life expectancy of >3 months                 │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has Hepatitis C in which participants received     │ Has hepatitis C in which participants received     │      99 │
│ therapy for HCV \<4 weeks prior to receiving       │ therapy for HCV <4 weeks prior to receiving        │         │
│ pembrolizumab                                      │ pembrolizumab                                      │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                      │   Score │
╞═══════════════════════════════════╪════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Has a life expectancy of >3 months │      39 │
╘═══════════════════════════════════╧════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 98.02941176470588
OverAll Ratio: 98.51470588235294
